Scott Alexander critically examines pharmacogenomic testing for antidepressants, particularly the GeneSight test, expressing skepticism about its current effectiveness and validity. Longer summary

Scott Alexander critically examines the field of pharmacogenomics for antidepressants, particularly focusing on the GeneSight test. He reviews the scientific evidence, discusses potential flaws in studies, and expresses skepticism about the current state and effectiveness of such testing. The post delves into the complexities of antidepressant metabolism, the challenges of predicting drug response, and the limitations of current genetic testing approaches. Shorter summary